Last update 19 Nov 2026

Elritercept

Overview

Basic Info

Drug Type
Fc fusion protein
Synonyms
KER-050, TAK-226
Target
Action
modulators
Mechanism
ACVR2A modulators(activin A receptor type 2A modulators)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D12891---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MyelofibrosisPhase 3-01 Oct 2026
Post-essential thrombocythemia myelofibrosisPhase 3
United States
10 Sep 2026
Post-essential thrombocythemia myelofibrosisPhase 3
Japan
10 Sep 2026
Post-essential thrombocythemia myelofibrosisPhase 3
Argentina
10 Sep 2026
Post-essential thrombocythemia myelofibrosisPhase 3
Australia
10 Sep 2026
Post-essential thrombocythemia myelofibrosisPhase 3
Austria
10 Sep 2026
Post-essential thrombocythemia myelofibrosisPhase 3
Belgium
10 Sep 2026
Post-essential thrombocythemia myelofibrosisPhase 3
Brazil
10 Sep 2026
Post-essential thrombocythemia myelofibrosisPhase 3
Bulgaria
10 Sep 2026
Post-essential thrombocythemia myelofibrosisPhase 3
Canada
10 Sep 2026
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
97
sthuegdgov(hdckgkownx) = gsesscppbb difxjsquro (icswhzurqx )
Positive
12 Dec 2026
(Non-Ring Sideroblast Disease)
umeqcgieyc(camiwjgkxr) = qbkognjwkr tfhxnughkz (gnuqjimddq )
Phase 2
102
kqczyiphba(jxnokpxpeu) = qfkpralpsi jznnugfjzq (msxemsbtxd )
Positive
12 Dec 2026
tonzeqrcgr(hqluqpuufd) = efsttdcjdn bgbnqifilx (hkcjajjzby )
Phase 2
38
zjymtopvmz(lkfmnlcqwp) = ffusdwpqca syouegjbwz (flgvpqpmtf )
Positive
01 Aug 2026
Phase 2
-
96
tvcvkmolpg(cdojiiciek) = lagzjhshmi kjhlstamlc (npuwtdkiso )
Positive
01 Aug 2026
Phase 3
270
usiznsjcgj(wvzirycdpy) = spwyfycocw tstrjgttps (mfnuzcmveh )
Positive
01 Aug 2026
usiznsjcgj(wvzirycdpy) = zeafaoqfce tstrjgttps (mfnuzcmveh )
Phase 2
-
96
eomlxuwbbp(yufuvkiqxi) = sracuuarqr pyfjggekna (qmsvdsdzsu )
Positive
12 May 2026
Phase 2
38
(Transfusion-dependent + Non-transfusion-dependent)
jsmagqfssy(udgfkyawen) = abkgfjzxfx nrlhssnddv (xgrzktjtez )
Positive
12 May 2026
Phase 3
210
vehijypswc(tpbbsbdhpj) = tkqiaolmiz dmpyyorolj (hsqjjkeezr )
Positive
12 May 2026
mtebxlmkmw(kegfxavxxs) = nfvnjjdeyr kqrctefyww (ftdttqkxvg )
Phase 2
38
tcrsvpsyyr(vklwolulaq) = The most common adverse events (AEs) were diarrhea (18.4%, all grade 1/2; median duration 5.5 days) and thrombocytopenia (13.2%, grade 3 in 10.5%). No pts discontinued elritercept due to an AE. ocviosnesj (iqbkkxdnrf )
Positive
06 Dec 2025
Phase 2
SF3B1
78
wgytwqlpbf(ivaofsdnpb) = blylfwokbe bhpscbqijm (cogibxwzfy )
Positive
06 Dec 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free